Fractyl Health

11/20/2025

Thank you to Malcolm Johnson NBC10 Boston of NBC10 Boston for highlighting our work at Fractyl Health and our vision for more durable approaches to and .

While medications have transformed the treatment landscape, many patients face challenges maintaining results once treatment stops. Our investigational and preclinical programs, Revita®, a procedural therapy being studied to remodel the duodenal lining and potentially improve metabolic health, and Rejuva®, our Smart GLP-1™ platform currently in preclinical development, are designed to explore ways to address a root cause of metabolic disease.

Watch the full NBC Boston story here: https://www.nbcboston.com/video/multimedia/what-to-know-about-weight-loss-drugs/3848313/

Revita® is for Investigational Use Only in the U.S. under Federal law. Rejuva® is in preclinical development and has not yet been evaluated by regulatory agencies.

As America rides a surging wave of GLP-1 medications like Ozempic and Wegovy, new questions are emerging about how long the treatments last and what happens when patients stop taking them.

12/27/2024

We’ve had a banner year at Fractyl Health. From going public, to presenting compelling data across the country to investors and scientists and receiving a Breakthrough Device designation from the FDA - we're celebrating our successes and looking to a big 2025 full of critical catalysts.

We're deeply appreciative of our employees, our Board, our investors, our physician partners, and most importantly our patients for propelling us forward each day and making significant strides in the fight against and . We look forward to continuing this momentum in 2025!

11/20/2024

We’re living our passion of developing breakthrough therapies to improve lives every day. See how Krysta Banfield, Diabetes Educator, finds innovative solutions for people living with and .

11/12/2024

We’re breaking the pattern of and .

Read more about Fractyl Health’s ( : GUTS) Q3 financial results and our potentially novel approach to weight maintenance here: https://bit.ly/4hMqGR2

11/08/2024

What a phenomenal week at ObesityWeek! We were thrilled to share our latest research and connect with brilliant minds dedicated to tackling and . Thank you to everyone who joined our presentations and engaged in insightful discussions. Together, we're making strides toward a healthier future.

To read our presentation, visit https://bit.ly/3AkC1aa

10/28/2024

We are excited to announce that Fractyl Health will be presenting cutting-edge research at ObesityWeek in San Antonio, TX. Join us for our oral and poster presentations where we'll share the latest advancements in tackling the unmet need in obesity – durable weight maintenance. Stay tuned for more updates!

10/25/2024

We've got some exciting news... we're rolling out a refreshed brand identity and website!

Our rebrand is a pivotal moment, reflecting the transition of Fractyl Health:

"This brand reflects the evolution of who we are as a company, where we’re headed, and our commitment to continue delivering exceptional, differentiated products to patients." - Harith Rajagopalan, Co-Founder and CEO

Check out our new look at fractyl.com.

10/15/2024

See what motivates Sam Berard, Senior Manufacturing Engineer, at work every day.

10/24/2022

We’re hiring across multiple departments! Interested in joining a team working towards a new approach to the treatment of ?
Check out our open positions: https://bit.ly/3IM8vts

10/13/2022

The Revitalize-1 study is enrolling people with taking long-acting insulin. Eligible participants receive all study-related health assessments at no cost, and health insurance is not required. See if you qualify: https://bit.ly/3adATod